MorphoSys AG at JPMorgan Healthcare Conference Transcript
Great. Good afternoon. I'm James Gordon, JPMorgan European Pharma and Biotech Analyst. And today, I've got the pleasure of introducing the MorphoSys presentation. And you're going to hear from MorphoSys CEO Jean-Paul Kress.
Thanks very much for joining us today. Looking forward to the presentation.
Thank you, James. Thanks for having me and very pleased to share with you the great progress we're making at MorphoSys. Please have a look at our forward-looking statement slide.
A few years ago, we redefined the strategy of the company, and we centered on oncology and more specifically, hematology oncology. And for that, we beefed up our pipeline with the acquisition of Constellation and mainly pelabresib, which is our number one opportunity. Pelabresib is a BET inhibitor, which has the potential to redefine the standard of care in myelofibrosis first line and establish a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
